The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving...

Area of Science:

• Interventional Radiology
• Oncology
• Hepatology

Background:

• Liver metastases significantly impact prognosis in breast cancer (BC).
• Transarterial radioembolization (TARE) is an emerging locoregional therapy for liver malignancies.
• Limited meta-analyses exist on TARE's efficacy specifically for liver metastatic BC.

Purpose of the Study:

• To meta-analyze the objective response rate (ORR) and disease control rate (DCR) of TARE in patients with liver metastatic BC.
• To evaluate TARE's utility as a treatment option for this patient population.

Main Methods:

• Systematic literature search for studies on TARE in liver metastatic BC.
• Inclusion criteria: ≥10 patients, adequate ORR and DCR data.
• ORR defined as complete response (CR) + partial response (PR); DCR as CR + PR + stable disease (SD).

Main Results:

• Eighteen studies (650 patients) met the criteria.
• Overall TARE ORR: 50.71% (95% CI: 40.04-61.36); DCR: 88.37% (95% CI: 81.89-93.57).
• Resin spheres showed higher ORR (60.35%) vs. glass spheres (32.38%), with comparable DCRs.

Conclusions:

• TARE demonstrates significant efficacy in managing liver metastatic breast cancer.
• Both resin and glass microsphere TARE are favorable treatment options.
• TARE offers a valuable therapeutic strategy for patients with liver-dominant BC.